Analysts Issue Forecasts for Insulet Co.’s Q3 2022 Earnings (NASDAQ:PODD)

Insulet Co. (NASDAQ:PODD – Get Rating) – Equities research analysts at William Blair increased their Q3 2022 EPS estimates for shares of Insulet in a research note issued on Monday, May 2nd. William Blair analyst M. Kaczor now forecasts that the medical instruments supplier will post earnings per share of $0.33 for the quarter, up from their prior forecast of $0.32.

Insulet (NASDAQ:PODD – Get Rating) last released its quarterly earnings data on Wednesday, February 23rd. The medical instruments supplier reported $0.42 earnings per share for the quarter, beating analysts’ consensus estimates of $0.30 by $0.12. Insulet had a return on equity of 9.47% and a net margin of 1.53%. The firm had revenue of $307.70 million during the quarter, compared to analyst estimates of $300.57 million. During the same quarter in the prior year, the firm posted ($0.26) earnings per share. The business’s quarterly revenue was up 25.0% compared to the same quarter last year.

PODD has been the subject of several other reports. Raymond James lowered their price objective on shares of Insulet from $329.00 to $280.00 and set an “outperform” rating for the company in a research note on Thursday, February 24th. Oppenheimer upgraded Insulet from a “market perform” rating to an “outperform” rating and dropped their price objective for the stock from $300.00 to $275.00 in a report on Monday, January 31st. Piper Sandler reduced their target price on Insulet from $295.00 to $230.00 and set a “neutral” rating on the stock in a research note on Thursday, February 24th. UBS Group raised Insulet from a “neutral” rating to a “buy” rating and set a $325.00 price target for the company in a research note on Wednesday, February 2nd. Finally, Morgan Stanley reduced their price objective on shares of Insulet from $300.00 to $268.00 and set an “equal weight” rating on the stock in a research report on Friday, February 25th. One analyst has rated the stock with a sell rating, three have issued a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, Insulet currently has an average rating of “Buy” and an average price target of $296.23.

Shares of PODD opened at $247.01 on Thursday. The stock has a market capitalization of $17.12 billion, a P/E ratio of 1,073.96 and a beta of 0.72. Insulet has a twelve month low of $193.70 and a twelve month high of $324.81. The company has a quick ratio of 4.49, a current ratio of 5.81 and a debt-to-equity ratio of 2.24. The firm has a fifty day simple moving average of $254.16 and a two-hundred day simple moving average of $264.20.

In other Insulet news, CEO Shacey Petrovic sold 15,000 shares of the stock in a transaction dated Monday, April 4th. The stock was sold at an average price of $273.25, for a total value of $4,098,750.00. Following the transaction, the chief executive officer now owns 13,607 shares of the company’s stock, valued at $3,718,112.75. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Wayde D. Mcmillan sold 1,455 shares of the business’s stock in a transaction dated Friday, April 1st. The shares were sold at an average price of $275.60, for a total value of $400,998.00. Following the sale, the chief financial officer now owns 21,354 shares of the company’s stock, valued at $5,885,162.40. The disclosure for this sale can be found here. Company insiders own 0.90% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Capital Research Global Investors grew its holdings in Insulet by 8.0% during the fourth quarter. Capital Research Global Investors now owns 7,811,512 shares of the medical instruments supplier’s stock valued at $2,078,434,000 after purchasing an additional 579,764 shares during the period. D1 Capital Partners L.P. increased its holdings in Insulet by 27.9% in the 4th quarter. D1 Capital Partners L.P. now owns 1,692,857 shares of the medical instruments supplier’s stock worth $450,418,000 after acquiring an additional 368,775 shares in the last quarter. Geode Capital Management LLC increased its holdings in Insulet by 5.7% in the 3rd quarter. Geode Capital Management LLC now owns 871,957 shares of the medical instruments supplier’s stock worth $247,483,000 after acquiring an additional 47,230 shares in the last quarter. Janus Henderson Group PLC raised its stake in Insulet by 48.0% during the 3rd quarter. Janus Henderson Group PLC now owns 853,753 shares of the medical instruments supplier’s stock worth $242,661,000 after acquiring an additional 277,056 shares during the period. Finally, Allspring Global Investments Holdings LLC bought a new position in shares of Insulet in the fourth quarter worth approximately $203,619,000.

Insulet Company Profile (Get Rating)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.

See Also